Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Carbetocin intranasal - Ferring Pharmaceuticals/Levo Therapeutics

Next Previous
Search
Drug Profile

Carbetocin intranasal - Ferring Pharmaceuticals/Levo Therapeutics

Alternative Names: ACP-101; FE-992097; LV 101

Latest Information Update: 23 May 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ferring Pharmaceuticals
  • Developer Levo Therapeutics
  • Class Antihaemorrhagics; Oxytocics; Posterior pituitary hormones
  • Mechanism of Action Oxytocin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Prader-Willi syndrome
  • New Molecular Entity No

Highest Development Phases

  • Phase III Prader-Willi syndrome

Most Recent Events

  • 11 Mar 2024 ACADIA Pharmaceuticals initiates enrolment in a phase III open-label extension trial in Prader-Willi syndrome (In children, In adolescents, in adults) in USA (Intranasal, Spray) (NCT06420297)
  • 31 Dec 2023 Carbetocin intranasal receives Rare Paediatric Disease designation from the US FDA for Prader-Willi syndrome, before December 2023
  • 30 Nov 2023 Phase-III clinical trials in Prader-Willi syndrome (In children, In adolescents, In adults) in USA (Intranasal) (NCT06173531)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top